Michael is an Investment Director at BDC, where he is a member of the Services investment team. He holds a degree in English language and literature from Oxford University. Michael joined the firm in 2017, and since joining he has been involved in several transactions, including investments in Prescient Healthcare Group, Fera, DataExpert, SK AeroSafety, Analysys Mason and Achilles, as well as the add-on acquisition of The Kenrich Group for HKA and the subsequent sale of HKA to PAI Partners. Prior to Bridgepoint Development Capital, he was an Associate in the Financial Sponsors Group at HSBC, where he advised private equity clients on several M&A and leveraged finance transactions.
Featured
The Living Launch Plan: Keeping Pharma Launch Strategy Aligned
Discover how a living launch plan helps pharmaceutical teams adapt to evolving evidence, competitive dynamics, and changing market conditions.
News and insights
Featured
The New Drivers of Pharma Launch Uptake
Learn why precision in launch strategy is becoming essential for improving pharmaceutical launch uptake and commercial performance.
One-Size-Fits-All Launches Are Over
Read the article to discover why modern pharma launches require a precision approach, helping teams prioritize Must-Win Moments, reduce risk, and improve launch success.
ONWARD: Driving Equitable Access and System Readiness in Cancer Care
This Dolon Institute paper highlights six interconnected barriers affecting timely access to oncology innovation, drawing on examples from healthcare systems around the world.
Careers
Work with us
If you're looking to stretch your thinking, lead with purpose, and be part of a culture that values curiosity, accountability and trust, you're in the right place.
